close
  • home Home

  • linked_services Solutions keyboard_arrow_down

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

  • mail Contact

  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu

The RIQAS Pre-eclampsia EQA Programme is designed to monitor a laboratories ability to correctly determine the outcome of the following tests, which are useful for screening, diagnosing, predicting and monitoring placenta related disorders; PAPP-A, PlGF, sFlt-1 and sFlt-1/PlGF ratio. Ensuring accuracy in Pre-eclampsia testing, helping to improve patient care and outcomes

Lyophilised material for enhanced stability

Submit results and view reports online via RIQAS.Net

World's largest EQA scheme ensuring peer groups are maximised

Monthly reporting for earlier identification of test system errors

Cycle Starts - July 2026

Not Accredited

Get in touch to discover more

To find out more about RIQAS EQA or to get in touch with your local Randox Representative, enquire now.

DescriptionFrequencySizeCat No
Pre-eclampsiaMonthly12 x 1mlRQ9207

Parameters

  • PAPP-A
  • sFlt-1
  • sFlt-1/PlGF ratio
  • PlGF

Related RIQAS EQA Programmes

Maternal Screening

General Clinical Chemistry

Specific Proteins

Acusera QC
Complete QC Solutions for Results you Can Trust
RIQAS Brochure
Randox International Quality Assessment Scheme
QCMD
QCMD EQA/PT Schemes for Molecular Infectious Disease Testing.